TSH Biopharm Corp. Ltd.
TTPEX:843254.70
TWD
-0.30
(-0.55%)
ISIN
TW0008432006
Return %
Stock
S&P 500
1Y
-1.26
14.20
3Y
18.78
81.12
5Y
22.51
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Ssu Yuan Yang
- Full Time Employees
- 70
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 3-1, Park Street Taipei TP Taiwan 11503
- IPO Date
- Apr 30, 2012
- Website
- tshbiopharm.com
- Similar Companies
- Business
- TSH Biopharm Corporation Limited is a Taiwan-based specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of branded and generic pharmaceutical products. The company focuses on therapeutic areas including cardiovascular diseases, central nervous system disorders, gastrointestinal diseases, and autoimmune conditions. Its core product portfolio includes cardiovascular drugs such as Amtrel (compound anti-hypertensives), Rytmonorm (arrhythmia treatment), Linicor and Cretrol (lipid-lowering agents), gastrointestinal drugs like Mopride for functional dyspepsia and Catilon for irritable bowel syndrome, as well as immunosuppressive drugs including Aleviatin, Lonine (for rheumatoid arthritis and osteoarthritis), and Lacoxa SR. In addition to pharmaceuticals, TSH Biopharm offers precision medicine services such as next-generation sequencing genetic testing and cancer diagnostics. Founded in 2010 and headquartered in Taipei, Taiwan, TSH Biopharm operates mainly within the Taiwanese domestic market but has expanded its product registrations and marketing to other Asian regions including Thailand, Myanmar, Hong Kong, and Macau. It is a subsidiary of TTY Biopharm Company Limited and actively pursues strategic investments in biotechnology firms like CYB Biotechnology and Top Pharma & Bio-Tech, enhancing its product portfolio and market reach in preventive medicine, vaccines, and elderly care products. Notable recent developments include the approval and launch of TYRVAYA® for dry eye disease nasal spray by the Taiwan FDA in 2024, marking a significant innovation in TSH's product offerings. The company also expanded its geographic footprint by officially launching the Lonine drug in Macau in 2025. Additionally, TSH Biopharm emphasizes corporate sustainability, having established a Sustainability Development Committee in 2022 and receiving recognition for its environmental and social initiatives at the 2025 Asia Responsible Enterprise Awards. The company continues strategic collaborations with partners in Korea and Spain to extend its cancer diagnostics and orthopedic product lines, and it actively engages in community health and sustainability programs in Taiwan. TSH Biopharm’s integrated approach combines pharmaceutical manufacturing, biotechnology research, precision medical testing, and market expansion across Asia, consolidating its position as a leading player in specialty pharmaceuticals focused on chronic and autoimmune diseases. The company maintains a diversified portfolio aimed at improving patient quality of life through innovative therapies and precision medicine solutions.